As director of the Center for Clinical and Translational Research at Seattle Children's Research Institute, Bonnie Ramsey, M.D., played a key role in the development of dornase alfa (Pulmozyme®), the first drug designed specifically for cystic fibrosis. She was also a leader in the development of inhaled tobramycin (TOBI®), the first aerosolized antibiotic used to treat CF lung infections.
By taking the lessons learned from these experiences and applying them to the creation of the Therapeutics Development Network (TDN), Dr. Ramsey helped grow the program into the largest CF clinical trials network in the world.
Today, the TDN is on the frontlines of expanding the Foundation's pipeline of approved and potential CF therapies, and boasts 82 clinical research centers that recruit study volunteers and conduct clinical trials.
After leading the TDN for 16 years, Dr. Ramsey is focusing on seeing patients in clinic and overseeing additional CF research projects. She remains actively involved with the TDN in her roles as a principal investigator and senior advisor.
Learn more about the Therapeutics Development Network by watching the video below.
